Literature DB >> 24287156

PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop.

Jos G Bessems1, George Loizou2, Kannan Krishnan3, Harvey J Clewell4, Camilla Bernasconi5, Frederic Bois6, Sandra Coecke5, Eva-Maria Collnot7, Walter Diembeck8, Lucian Romeo Farcal5, Liesbeth Geraets9, Ursula Gundert-Remy10, Nynke Kramer11, Gabriele Küsters12, Sofia B Leite13, Olavi R Pelkonen14, Klaus Schröder15, Emanuela Testai16, Iwona Wilk-Zasadna5, José-Manuel Zaldívar-Comenges5.   

Abstract

Information on toxicokinetics is critical for animal-free human risk assessment. Human external exposure must be translated into human tissue doses and compared with in vitro actual cell exposure associated to effects (in vitro-in vivo comparison). Data on absorption, distribution, metabolism and excretion in humans (ADME) could be generated using in vitro and QSAR tools. Physiologically-based toxicokinetic (PBTK) computer modelling could serve to integrate disparate in vitro and in silico findings. However, there are only few freely-available PBTK platforms currently available. And although some ADME parameters can be reasonably estimated in vitro or in silico, important gaps exist. Examples include unknown or limited applicability domains and lack of (high-throughput) tools to measure penetration of barriers, partitioning between blood and tissues and metabolic clearance. This paper is based on a joint EPAA--EURL ECVAM expert meeting. It provides a state-of-the-art overview of the availability of PBTK platforms as well as the in vitro and in silico methods to parameterise basic (Tier 1) PBTK models. Five high-priority issues are presented that provide the prerequisites for wider use of non-animal based PBTK modelling for animal-free chemical risk assessment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AD; Development stage; In silico (QSAR) tools; In vitro methods; PBTK; SPME; Tier 1 model; applicability domain; physiologically-based toxicokinetic; solid phase microextraction

Mesh:

Substances:

Year:  2013        PMID: 24287156     DOI: 10.1016/j.yrtph.2013.11.008

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  27 in total

1.  The European Partnership for Alternative Approaches to Animal Testing (EPAA): promoting alternative methods in Europe and beyond.

Authors:  Gwenole Cozigou; Jonathan Crozier; Coenraad Hendriksen; Irene Manou; Tzutzuy Ramirez-Hernandez; Renate Weissenhorn
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-03       Impact factor: 1.232

Review 2.  Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.

Authors:  Darren Michael Moss; Marco Siccardi
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

3.  Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report.

Authors:  Amy J Clippinger; David Allen; Annie M Jarabek; Marco Corvaro; Marianna Gaça; Sean Gehen; Jon A Hotchkiss; Grace Patlewicz; Jodie Melbourne; Paul Hinderliter; Miyoung Yoon; Dongeun Huh; Anna Lowit; Barbara Buckley; Michael Bartels; Kelly BéruBé; Daniel M Wilson; Ian Indans; Mathieu Vinken
Journal:  Toxicol In Vitro       Date:  2017-12-22       Impact factor: 3.500

4.  Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics.

Authors:  John F Wambaugh; Michael F Hughes; Caroline L Ring; Denise K MacMillan; Jermaine Ford; Timothy R Fennell; Sherry R Black; Rodney W Snyder; Nisha S Sipes; Barbara A Wetmore; Joost Westerhout; R Woodrow Setzer; Robert G Pearce; Jane Ellen Simmons; Russell S Thomas
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

5.  Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.

Authors:  Abdulkarim Najjar; Ans Punt; John Wambaugh; Alicia Paini; Corie Ellison; Styliani Fragki; Enrica Bianchi; Fagen Zhang; Joost Westerhout; Dennis Mueller; Hequn Li; Quan Shi; Timothy W Gant; Phil Botham; Rémi Bars; Aldert Piersma; Ben van Ravenzwaay; Nynke I Kramer
Journal:  Arch Toxicol       Date:  2022-09-05       Impact factor: 6.168

Review 6.  Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Authors:  Hannu Raunio; Mira Kuusisto; Risto O Juvonen; Olli T Pentikäinen
Journal:  Front Pharmacol       Date:  2015-06-12       Impact factor: 5.810

7.  Toxicology: a discipline in need of academic anchoring--the point of view of the German Society of Toxicology.

Authors:  U Gundert-Remy; H Barth; A Bürkle; G H Degen; R Landsiedel
Journal:  Arch Toxicol       Date:  2015-08-28       Impact factor: 5.153

Review 8.  Animal-Free Chemical Safety Assessment.

Authors:  George D Loizou
Journal:  Front Pharmacol       Date:  2016-07-21       Impact factor: 5.810

9.  Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Authors:  Alicia Paini; Jeremy A Leonard; Tomas Kliment; Yu-Mei Tan; Andrew Worth
Journal:  Regul Toxicol Pharmacol       Date:  2017-09-01       Impact factor: 3.271

10.  The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine.

Authors:  Jos G M Bessems; Alicia Paini; Monika Gajewska; Andrew Worth
Journal:  Toxicology       Date:  2017-03-10       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.